Intellia Therapeutics (NTLA) Downgraded by ValuEngine to “Hold”

ValuEngine lowered shares of Intellia Therapeutics (NASDAQ:NTLA) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

NTLA has been the topic of a number of other reports. Raymond James began coverage on shares of Intellia Therapeutics in a report on Thursday, September 20th. They set a market perform rating on the stock. BidaskClub lowered shares of Intellia Therapeutics from a buy rating to a hold rating in a report on Friday, September 7th. Zacks Investment Research lowered shares of Intellia Therapeutics from a buy rating to a hold rating in a report on Tuesday, August 7th. Finally, Chardan Capital reissued a buy rating and set a $57.50 target price on shares of Intellia Therapeutics in a report on Friday, August 24th. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $39.50.

NTLA opened at $27.09 on Friday. Intellia Therapeutics has a fifty-two week low of $16.33 and a fifty-two week high of $35.99. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -14.41 and a beta of 3.08.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, August 1st. The company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm had revenue of $7.68 million for the quarter, compared to analyst estimates of $6.39 million. During the same period in the previous year, the firm posted ($0.45) EPS. The company’s revenue for the quarter was up 30.2% compared to the same quarter last year. equities analysts predict that Intellia Therapeutics will post -1.97 earnings per share for the current fiscal year.

In other news, Director Jean Francois Formela sold 6,686 shares of the business’s stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $31.17, for a total value of $208,402.62. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of NTLA. Macquarie Group Ltd. acquired a new position in shares of Intellia Therapeutics in the 2nd quarter worth approximately $101,000. Legal & General Group Plc lifted its position in shares of Intellia Therapeutics by 75.4% in the 2nd quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock worth $149,000 after purchasing an additional 2,333 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Intellia Therapeutics by 519.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,733 shares of the company’s stock worth $157,000 after purchasing an additional 4,807 shares during the period. Sei Investments Co. lifted its position in shares of Intellia Therapeutics by 633.3% in the 2nd quarter. Sei Investments Co. now owns 5,866 shares of the company’s stock worth $160,000 after purchasing an additional 5,066 shares during the period. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Intellia Therapeutics in the 2nd quarter worth approximately $203,000. Hedge funds and other institutional investors own 66.50% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Further Reading: Why Dividend Stocks May Be Right for You

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply